Product Information
PIMECROLIMUS 1% CREAM is a generic product labeled by Actavis Pharma, Inc., priced at $3.1048 per GM under NDC 00591294460. Its NADAC has been published 394 times since Mar 20, 2019.
FDA first approved this application on Dec 27, 2018. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
10 mg/g
Manufacturer
Actavis Pharma, Inc.NDC
00591294460
Classification
Generic
Dosage Form
CREAM
Route
TOPICAL
Effective Date
9/23/2026
Active Ingredients
PIMECROLIMUSApproval Type
Generic (ANDA)
FDA Application
ANDA209345FDA Approved
12/27/2018
TE Code
AB
On Market Since
12/27/2018
Pharmacological Classes
Price Statistics
The NADAC for PIMECROLIMUS 1% CREAM has been published 394 times since Mar 20, 2019, and over the history we have for it it has declined 56.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $3.1048 per GM |
|---|---|
| All-time high | $7.6588 (Apr 15, 2020) |
| All-time low | $2.0962 (Nov 20, 2024) |
| 52-week high | $3.2132 |
| 52-week low | $2.6896 |
| Median price | $3.9707 |
| Average price | $4.3609 |
| Largest weekly change | -28.4% (Nov 20, 2024) |
| Weeks tracked | 394 |
| Tracking since | Mar 20, 2019 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Actavis Pharma, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
pimecrolimus market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Calcineurin Inhibitor Immunosuppressant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of PIMECROLIMUS 1% CREAM?
The current National Average Drug Acquisition Cost (NADAC) for PIMECROLIMUS 1% CREAM, manufactured by Actavis Pharma, Inc., is $3.1048 per GM (NDC 00591294460), effective Sep 30, 2026.
How has the price of PIMECROLIMUS 1% CREAM changed over time?
Over the history we have for it, the NADAC for PIMECROLIMUS 1% CREAM has declined 56.7%. It has been tracked across 394 weekly CMS publications since Mar 20, 2019.
What are the highest and lowest recorded NADAC prices for PIMECROLIMUS 1% CREAM?
Since Mar 20, 2019, the NADAC for PIMECROLIMUS 1% CREAM has ranged from a low of $2.0962 (Nov 20, 2024) to a high of $7.6588 (Apr 15, 2020), with a median of $3.9707 per GM.
Are there cheaper alternatives to PIMECROLIMUS 1% CREAM?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as PIMECROLIMUS 1% CREAM in a comparable dosage form, but none are currently priced below it.
Who manufactures PIMECROLIMUS 1% CREAM?
PIMECROLIMUS 1% CREAM (NDC 00591294460) is labeled by Actavis Pharma, Inc., and CMS classifies it as a generic product.